166 related articles for article (PubMed ID: 37749329)
1. Potential value of mitochondrial regulatory pathways in the clinical application of clear cell renal cell carcinoma: a machine learning-based study.
Qi X; Ge Y; Yang A; Liu Y; Wang Q; Wu G
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17015-17026. PubMed ID: 37749329
[TBL] [Abstract][Full Text] [Related]
2. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning.
Bai Z; Lu J; Chen A; Zheng X; Wu M; Tan Z; Xie J
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551318
[TBL] [Abstract][Full Text] [Related]
3. Predicting prognosis, immunotherapy and distinguishing cold and hot tumors in clear cell renal cell carcinoma based on anoikis-related lncRNAs.
Hao C; Li R; Lu Z; He K; Shen J; Wang T; Qiu T
Front Immunol; 2023; 14():1145450. PubMed ID: 37359524
[TBL] [Abstract][Full Text] [Related]
4. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.
Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X
Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
6. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
Chen Y; He J; Jin T; Zhang Y; Ou Y
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of ADAM8 inhibits the proliferation, migration, invasion, and tumorigenesis of renal clear cell carcinoma cells to enhance the immunotherapy efficacy.
Qu H; Mao M; Wang K; Mu Z; Hu B
Transl Res; 2024 Apr; 266():32-48. PubMed ID: 37992987
[TBL] [Abstract][Full Text] [Related]
8. Integration analysis identifies MYBL1 as a novel immunotherapy biomarker affecting the immune microenvironment in clear cell renal cell carcinoma: Evidence based on machine learning and experiments.
Wang T; Jian W; Xue W; Meng Y; Xia Z; Li Q; Xu S; Dong Y; Mao A; Zhang C
Front Immunol; 2022; 13():1080403. PubMed ID: 36591240
[TBL] [Abstract][Full Text] [Related]
9. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
10. An Integrated Machine Learning Framework Identifies Prognostic Gene Pair Biomarkers Associated with Programmed Cell Death Modalities in Clear Cell Renal Cell Carcinoma.
Chen B; Zhou M; Guo L; Huang H; Sun X; Peng Z; Wu D; Chen W
Front Biosci (Landmark Ed); 2024 Mar; 29(3):121. PubMed ID: 38538287
[TBL] [Abstract][Full Text] [Related]
11. Identification of an immunogenic cell death-related gene signature predicts survival and sensitivity to immunotherapy in clear cell renal carcinoma.
Zhou S; Lu Y; Chen Y; Gan W
Sci Rep; 2023 Mar; 13(1):4449. PubMed ID: 36932108
[TBL] [Abstract][Full Text] [Related]
12. Identification and Validation of the Prognostic Panel in Clear Cell Renal Cell Carcinoma Based on Resting Mast Cells for Prediction of Distant Metastasis and Immunotherapy Response.
Su Y; Zhang T; Lu J; Qian L; Fei Y; Zhang L; Fan S; Zhou J; Tang J; Chen H; Liang C
Cells; 2023 Jan; 12(1):. PubMed ID: 36611973
[TBL] [Abstract][Full Text] [Related]
13. Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma.
Xu C; Li Y; Su W; Wang Z; Ma Z; Zhou L; Zhou Y; Chen J; Jiang M; Liu M
Aging (Albany NY); 2022 Sep; 14(17):6917-6935. PubMed ID: 36057262
[TBL] [Abstract][Full Text] [Related]
14. Immune regulation and prognosis indicating ability of a newly constructed multi-genes containing signature in clear cell renal cell carcinoma.
Gui Z; Du J; Wu N; Shen N; Yang Z; Yang H; Wang X; Zhao N; Zeng Z; Wei R; Ma W; Wang C
BMC Cancer; 2023 Jul; 23(1):649. PubMed ID: 37438709
[TBL] [Abstract][Full Text] [Related]
15. Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma.
Chen M; Nie Z; Huang D; Gao Y; Cao H; Zheng L; Zhang S
Front Immunol; 2022; 13():1048204. PubMed ID: 36505496
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy and Immune Infiltration in Patients with Clear Cell Renal Cell Carcinoma: A Comprehensive Analysis.
Hou L; Liu X
Genet Res (Camb); 2023; 2023():3898610. PubMed ID: 37065178
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of an immune-related gene prognostic signature for clear cell renal carcinoma.
Hua S; Xie Z; Zhang Y; Wu L; Shi F; Wang X; Xia S; Dong S; Jiang J
Front Immunol; 2022; 13():869297. PubMed ID: 35936012
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma.
Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z
Front Immunol; 2022; 13():934243. PubMed ID: 36189255
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of prognostic and tumor microenvironment characteristics of necroptosis index and BIRC3 in clear cell renal cell carcinoma.
Wei K; Zhang X; Yang D
PeerJ; 2023; 11():e16643. PubMed ID: 38130918
[TBL] [Abstract][Full Text] [Related]
20. A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinoma.
Zhang L; Chen Y; Hu W; Wu B; Ye L; Wang D; Bai T
Front Immunol; 2023; 14():1230267. PubMed ID: 37600792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
